Changmao Bio projects H1 2026 net loss to narrow to RMB4–6 million, vs. RMB25.79 million a year earlier

Bulletin Express
08/03

Changmao Biochemical Engineering Company Limited said it expects to report a consolidated net loss attributable to shareholders of between RMB4 million and RMB6 million for the six months ended 30 June 2026. The projected figure marks a sharp improvement from the RMB25.79 million loss recorded in the same period of 2025.

Management attributed the reduced loss to two main factors: 1. Optimised product mix and expanded production capacity in response to market demand, which lifted both revenue and gross profit. 2. Progressive market expansion for products from the phase-II production line of subsidiary Changmao (Dalian) New Material Company Limited, helping to narrow net losses at that unit.

The figures are based on the Group’s unaudited management accounts; full interim results are scheduled for release on 18 August 2026. The company advised shareholders and potential investors to exercise caution when dealing in its shares.

免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。

热议股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10